Amgen, Finally Some Good News (AMGN, MRK)

Health and Healthcare

Published: May 19, 2008 4:01 pm

Last Updated: March 26, 2020 12:17 pm

Shares of Amgen Inc. (NASDAQ: AMGN) are seeing a small gain in after-hours trading.

The troubled biotech giant announced that findings from its head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). This study was a one-year non-pivotal Phase III study and it demonstrated superior results for the primary and all secondary endpoints.

The primary endpoint was in the total hip and it was listed as 80% greater in the group. This was a twice-yearly subcutaneous injection in a double-blind group of 504 women who suffered from low BMD.

FOSAMAX is an osteoporosis drug from Merck & Co. (NYSE: MRK).

Jon C. Ogg
May 19, 2008

Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.